35岁以下患者颅内脑膜瘤:人类免疫缺陷病毒感染时代的疾病演变
该研究连续纳入2003年5月至2015年5月诊断的≤35岁颅内脑膜瘤患者,按HIV-1血清状态分组比较组织病理分级。HIV-1血清阳性与高级别(WHO II/III级)脑膜瘤风险升高相关(OR 2.9,95%CI 1.06-8.09,P=0.04)。WHO分级与年龄、性别、种族/民族或部位无显著关联。
要点
- HIV-1血清阳性患者高级别(WHO II/III级)脑膜瘤风险升高(OR 2.9,95%CI 1.06-8.09,P=0.04)。
- WHO分级与年龄、性别、种族/民族或肿瘤部位无显著关联。
- 年轻HIV-1阳性患者的颅内脑膜瘤趋于高级别,保守或非侵入性治疗应谨慎并在组织诊断确认良性WHO分级后提供。
核心结论
- 年轻HIV-1阳性患者的颅内脑膜瘤趋于高级别;保守或非侵入性治疗应谨慎,并仅在组织诊断确认良性WHO分级后提供。
研究设计与样本
- 研究连续纳入2003年5月至2015年5月诊断的≤35岁颅内脑膜瘤患者,年龄分为<20岁、21-30岁和>30岁,按2000年WHO分级系统分为I、II、III级,患者分为HIV-1血清阳性组和 presumed seronegative 的一般人群组。
主要发现
- HIV-1血清阳性与高级别(WHO II/III级)脑膜瘤发生风险升高相关(OR 2.9,95%CI 1.06-8.09,P=0.04),对照为一般人群脑膜瘤患者。
- WHO分级与年龄、性别、种族/民族或部位之间未发现显著关联。
关键数值与推荐
- 高级别脑膜瘤定义为WHO II/III级。
- HIV-1血清阳性组较一般人群组高级别脑膜瘤风险升高(OR 2.9,95%CI 1.06-8.09,P=0.04)。
临床怎么用
- 作者认为,年轻HIV-1阳性患者的颅内脑膜瘤趋于高级别,保守或非侵入性治疗应谨慎,并仅在组织诊断确认良性WHO分级后提供。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intracranial meningiomas are most common among patients in their fifth to seventh decade of life and rare in children and young adults. They constitute 1.5% of all neoplasms in patients age <20 years, but account for 13.5% of all neoplasms in patients age 20-34 years. They are often associated with hereditary or familial syndromes in children and young adults, and tend to be of high grade. Here we describe the histopathological subtypes of intracranial meningioma between human immunodeficiency virus 1 (HIV-1)-seropositive patients and the general population with intracranial meningiomas 35 years old and younger. METHODS: Data were collected from all consecutive patients age ≤35 years diagnosed with intracranial meningioma between May 2003 and May 2015. Age was categorized as <20 years, 21-30 years, and >30 years. Histopathological grade was classified according to the 2000 World Health Organization (WHO) grading system as grade I, II, or III. Patients were grouped into an HIV-1-seropositive group and the general population, presumed seronegative. WHO grade II/III meningioma represented high-grade meningioma. RESULTS: HIV-1-seropositive status was associated with increased risk of the development of high-grade (WHO grade II/III) meningioma (odds ratio, 2.9; 95% confidence interval, 1.06-8.09; P = 0.04) compared with the general population of patients with meningiomas. No significant associations were found between WHO grade and age, sex, ethnicity/race, or location. CONCLUSIONS: Intracranial meningiomas in young HIV-1-positive patients tend to be of high grade; therefore, conservative or noninvasive therapies should be offered with caution and only after tissue diagnosis has confirmed benign WHO grade.
引用
- Motebejane MS, Kaminsky I, Choi IS, et al. Intracranial Meningioma in Patients Age <35 Years: Evolution of the Disease in the Era of Human Immunodeficiency Virus Infection. World Neurosurg. 2017. PMID: 28987830. doi:10.1016/j.wneu.2017.09.161
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。